LATEST
Janel agreed to acquire EnCor BiotechnologynewNightfood Holdings acquired Jun Long Machine IndustrialnewClimb Global Solutions acquired NeoVADnewValor Energy agreed to acquire Glorious StarOakley Capital / Global Loan Agency ServicesTA Associates / MedEnvision: majority stakeLSEG agreed to acquire OctusStord / AMS Fulfillment: investmentCencora agreed to acquire American Oncology NetworkAPEX / KoraiSmith & Wesson Brands agreed to acquire Long Range IntermediateBose acquired Skullcandy
Open App
Agreement signedPublished 14 Jul 2022

Royalty Pharma /
Theravance Biopharma

Royalty Pharma to buy Theravance Biopharma’s TRELEGY royalty interest

Terms
Not stated
Stage
Agreement signed
Buy side: Royalty Pharma
Buy sideRoyalty Pharma
Source · 14 Jul 2022
See the source
Buy side: Royalty Pharma
Buy sideRoyalty Pharma
01 / BuyerRoyalty Pharma
02 / TargetTheravance Biopharma
01

What happened

Royalty Pharma agreed to buy Theravance Biopharma’s 85% economic interest in sales-based royalty rights on worldwide net sales of TRELEGY ELLIPTA. The transaction has potential total value of over $1.5 billion.

The transaction is subject to limited closing conditions and is expected to close 10 business days after the announcement.

02

The source

Everything on this page comes from the source below.

01
Source · Source

Royalty Pharma to buy Theravance Biopharma’s TRELEGY royalty interest

This document is the source for the companies, stage and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by the source

    The source this page is built from.

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request accessAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.